To investigate the clinical utility of PHD inhibition for AML treatment, we determined the impact of Dap and IOX5 on AML patient samples, focusing on poor-risk AML, which is characterized by a particularly low overall patient survival rate2. The gene discussed is PDC; the disease is acute myeloid leukemia.